Big Pharma Split Corp.

PRM.TO · TSX
Analyze with AI
Key StatsIncome StatementBalance SheetCash Flow
AnnualQuarterly
KMB
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets––––
Cash & EquivalentsCA$1CA$0CA$1CA$1
Short-Term InvestmentsCA$25CA$0CA$0CA$0
ReceivablesCA$0CA$0CA$14CA$0
InventoryCA$0CA$0-CA$1-CA$1
Other Curr. Assets-CA$25CA$1CA$1CA$1
Total Curr. AssetsCA$1CA$1CA$15CA$2
Property Plant & Equip (Net)CA$0CA$0CA$0CA$0
GoodwillCA$0CA$0CA$0CA$0
IntangiblesCA$0CA$0CA$0CA$0
Long-Term InvestmentsCA$25CA$1CA$1CA$1
Tax AssetsCA$0CA$0CA$0CA$0
Other NC AssetsCA$0CA$0CA$0CA$0
Total NC AssetsCA$25CA$1CA$1CA$1
Other AssetsCA$0CA$0CA$0CA$0
Total AssetsCA$26CA$27CA$39CA$38
Liabilities––––
PayablesCA$0CA$0CA$0CA$0
Short-Term DebtCA$12CA$10CA$10CA$15
Tax PayableCA$0CA$0CA$0CA$0
Deferred RevenueCA$0CA$0CA$0CA$0
Other Curr. Liab.CA$0-CA$10CA$9-CA$15
Total Curr. Liab.CA$12CA$0CA$19CA$0
LT DebtCA$0CA$0CA$0CA$0
Deferred Rev, NCCA$0CA$0CA$0CA$0
Deferred Tax Liab, NCCA$0CA$0CA$0CA$0
Other NC Liab.CA$1CA$0CA$0CA$0
Total NC Liab.CA$1CA$0CA$0CA$0
Other LiabilitiesCA$13CA$0CA$19CA$15
Cap. LeasesCA$0CA$0CA$0CA$0
Total LiabilitiesCA$13CA$11CA$19CA$15
Equity––––
Pref StockCA$0CA$0CA$0CA$0
Common StockCA$14CA$16CA$20CA$22
Retained EarningsCA$0CA$0CA$0CA$0
AOCICA$0CA$0CA$0CA$0
Other EquityCA$0CA$16CA$20CA$22
Total EquityCA$14CA$16CA$20CA$22
Supplemental Information––––
Minority InterestCA$0CA$0CA$0CA$0
Total Liab. & Tot. EquityCA$26CA$27CA$39CA$38
Net DebtCA$11CA$10CA$9CA$13